Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P00750 (PLA)
 16,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An increased blood fibrinolytic activity manifested by increased tissue plasminogen activator (t-PA) and decreased tissue plasminogen activator inhibitor (PAI-1) and increased FDP levels are seen in 40 patients with mild hypertrophy of prostate. Surgical treatment increased blood fibrinolytic activity manifested in the increase in t-PA, decrease in PAI-1, shortening of ELT, increase in FDP, and decrease in plasminogen and 2-AP activities. Blood fibrinolytic activity was the highest immediately after surgery with tendency to the gradual normalization. Positive ethanol test and decrease in thrombocyte count indicate and activation of blood clotting system induced by the tissue thrombo-elastins released during surgery. Subclinical DCI with the secondary increased fibrinolysis activation is present in patients with mild hypertrophy of the prostate both prior to and after surgery.
Pol Tyg Lek
PMID:[Tissue plasminogen activator, its inhibitor and other parameters of fibrinolysis in blood of patients operated for mild hypertrophy of the prostate]. 128 28

The paper describes the results of the studies on structure and function of the tissue-type plasminogen activator collected for the past 10 years. The properties of one- and two-chain t-PA as well as the structure of the particular domains in the t-PA molecule have been characterized and discussed.
Acta Haematol Pol 1992
PMID:[Tissue-type plasminogen activator (T-PA). Structure and function]. 149 40

In 50 patients operated on from various gynaecological indications the haemostasis system was monitored determining its parameters before and 2 hours after the operation and again after 5 days. Besides routine tests of platelet-related haemostasis, clotting system and fibrinolysis the fibrinolytic activity was assessed in dynamic tests after venous stasis. The obtained results confirmed the presence of a tendency for development of the disseminated intravascular clotting syndrome with associated fibrinolysis activation immediately after the operation. On the fifth day a tendency was noted for thromboembolic complications which was prevented by increased synthesis of plasminogen activator in the vascular wall. The study confirmed the usefulness of prophylactic doses of heparin in patients with presence of risk factors. In the light of own investigations and a survey of the pertinent literature the authors suggest that simultaneous administration of small subcutaneous doses of heparin and application of intermittent compression would be the most adequate method of thrombosis prevention after operations in the small pelvis.
Ginekol Pol 1989 Jun
PMID:[Dynamic assessment of hemostasis after gynecological operations. I. Effect of gynecological operations on hemostatic function]. 263 97

The effect of mercuric chloride on blood coagulation and fibrinolysis in rats was studied. The mercurial was administered to the animals intragastrically in a single dose of 17.9 mg Hg/kg and the effects were tested on the 1st, 3rd and 7th day. The symptoms of hypercoagulability accompanied by decreased fibrinolytic activity of the plasma were observed in the poisoned rats. The main reason of the lowered fibrinolytic activity seemed to be the inhibition of plasma plasminogen activator or the inhibition of plasminogen activation reaction catalyzed by this enzyme.
Pol J Pharmacol Pharm
PMID:Coagulation and fibrinolysis in rats poisoned with mercuric chloride. 314 50

Methods for measuring antigen and activity of plasminogen activators (t-PA, u-PA), plasminogen activator inhibitors (PAI-1, PAI-2) and their complex have been improved in the past few years, but few comparative data are available and they should be standardized. In particular the commercial kits for determination of PAI-1 activity seem to be not accurate for the measurement of PAI-1 in plasma. The amount of generated plasmin can be measured as plasmin-alpha-2-antiplasmin complex (PAP). There are also some new tests which could differentiate between fibrinogenolysis (FgDP) and fibrinolysis (FnDP, D-dimer) as between primary and secondary activation of fibrinolysis (B beta 15-42 peptide). Normal D-dimer plasma concentration allows for the ruling out of venous thromboembolism with high probability, but the specificity of this tests is poor.
Acta Haematol Pol 1995
PMID:[Progress in the detection of intravascular activation of fibrinolysis]. 774 60

The aim of this study was to compare the secretory response of the vascular wall in vivo to DDAVP (i.v. 0.3 microgram/kg, 30 min) and to venous occlusion (VO, 20 min) in control healthy subjects, patients with von Willebrand's disease type I (vWd I) and patients with von Willebrand's disease type III (vWd III). In controls (n = 10) and vWd I (n = 12), DDAVP induced a 2 to 3-fold rise in plasma von Willebrand factor antigen (vWf: Ag), factor VIII coagulant activity (VIII: C) and tissue--type plasminogen activator antigen (t-PA:Ag). VO was less effective in increasing vWf: Ag and VIII:C but produced a greater rise in t-PA:Ag. Large increments (over 10-fold) were observed in plasmin-alpha 2-antiplasmin complexes following both stimuli. In vWd III (n = 10), DDAVP and VO failed to increase vWf:Ag, VIII:C and t-PA:Ag. No significant changes in plasmin-alpha 2-antiplasmin complexes were observed in this group. Moreover, the baseline t-PA:Ag values were significantly lower in vWd III (2.17 +/- 1.13 ng/ml) than in controls (4.84 +/- 1.97 ng/ml, p < 0.001). A significant increase in urokinase--type plasminogen activator antigen (u-PA:Ag) was found only in controls after VO. Neither controls nor patients with vWd showed any changes in plasma fibronectin levels following DDAVP. The low t-PA:Ag results and the abnormal fibrinolytic response to DDAVP and VO in patients with severe (type III) vWd indicate that their endothelial cell abnormality is more extensive than the defect in the synthesis or release of vWf.
Acta Haematol Pol 1994
PMID:Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease. 799 99

To examine whether the epidermal growth factor (EGF)-like domain Pro47-Asp87 is involved in the interaction of tissue plasminogen activator (t-PA) with platelets, we have expressed this domain in E. coli. The peptide fragment was produced from a plasmid expression vector as a fusion protein with beta-galactosidase Met1-Val444 at high yield in eight clones of E. coli. The fusion protein was purified and subjected to mild acid hydrolysis with formic acid, then the peptide Pro47-Asp87, identified by immunoblotting using specific antibodies to t-PA, was isolated by HPLC. After incubation with blood platelets spin labelled with 16-doxylstearic acid or 5-doxylstearic acid, the Pro47-Asp87 peptide fragment reduced fluidity of the membrane lipid bilayer to the same extent as did intact t-PA as indicated by ESR measurements. Our data suggest that the EGF-like domain of t-PA can directly interact with blood platelets and thus it seems to contain those sites of the t-PA molecule that bind the platelet membrane components.
Acta Biochim Pol 1994
PMID:The epidermal growth factor-like domain from tissue plasminogen activator. Cloning in E. coli, purification and ESR studies of its interaction with human blood platelets. 803 Mar 71

Fibrinolytic activity and tissue plasminogen activator (t-PA) level were measured in 33 healthy individuals prior to and after fibrinolytic system stimulation (i.e. a ten-minute venous stasis). Fibrinolytic activity was measured with the aid of euglobin lysis time, and lysis test on the fibrin plates (in own modification). Tissue plasminogen activator concentration was assayed spectrophotometrically with the COA-SET t-PA (Kabi Vitrum). No fibrinolytic activity of plasma specimens taken before the venous stasis was noted during fibrin lysis plate test whereas it was seen in 13 subjects after the venous stasis. Fibrinolytic activity of the plasma euglobins, measured as a surface on fibrin plates, increased significantly after the venous stasis in both sexes (by 35.5 mm2 on the average, i.e. by 51%). It was more marked in men than in women both prior to and after venous stasis (by 10.9% and 19.0%, respectively). A time of plasma euglobin lysis was shorter after venous stasis (by 110 minutes, on the average). There was no significant difference between the sexes. Tissue plasminogen activator concentration increased by 5.8 times (from 1.7 IU/ml to 9.9 IU/ml) after the stasis. Correlation between t-PA concentrations and fibrinolytic activity, measured on the fibrin plates, was highly positive. No such a correlation existed between t-PA concentrations and the time of euglobin lysis. The obtained results indicate variety of assessments of fibrinolytic system activity.(ABSTRACT TRUNCATED AT 250 WORDS)
Pol Tyg Lek
PMID:[Fibrinolytic activity and tissue plasminogen activator level in healthy individuals prior to and after a ten-minute venous stasis]. 836 5

In 30 patients with prostatic carcinoma a higher of t-PA, a low of PAI-1, alpha 2-antiplasmin and plasminogen activity with increased fibrin degradation products (FDP) level and a short euglobulin lysis time (ELT) were observed. Following surgery a further increased of fibrinolytic activity occurred. The activity of t-PA and PAI-1 were higher than before operation. Apart from that we observed a decreased of plasminogen and alpha 2-AP with further increased level of FDP. On 5-th day the values of examined parameters were similar as before the operation.
Pol Tyg Lek 1996 Feb
PMID:[Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma]. 875 41

We reported on a 74 year old patients with local advanced prostatic carcinoma. Following prostatic surgery an increased bleeding tendency was observed. The patients showed clinical and laboratory evidence for consumption coagulopathy with hyperfibrinolysis. The laboratory data were: marked decrease of AT III, Protein C, increase of thrombin/AT III complex level, fibrin degradation products (FDP) and antigen of t-PA. The treatment was ended successful.
Pol Tyg Lek 1996 Feb
PMID:[Disseminated intravascular coagulation syndrome with secondary fibrinolysis activation in prostatic carcinoma]. 875 45


1 2 3 4 5 6 Next >>